Market research
ZLAB Zai Lab Ltd
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 3B
- P/E ratio
- Not available
- Analyst target
- 32.39
- Dividend yield
- Not available
- Beta
- 0.78
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US98887Q1040
- Market cap
- 3B
- P/E ratio
- Not available
- Analyst target
- 32.39
- Dividend yield
- Not available
- Beta
- 0.78
About
About Zai Lab Ltd
Zai Lab Limited, a biopharmaceutical company, focuses on discovering, developing, and commercializing products that address medical conditions in the areas of oncology, immunology, neuroscience, and infectious diseases. Its commercial products include Zejula, an orally administered poly (ADP-ribose) polymerase 1/2 inhibitor for treating ovarian cancer; VYVGART, a human IgG1 antibody fragment for generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy; NUZYRA for community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections; Optune for glioblastoma multiforme; Qinlock for gastrointestinal stromal tumors; Xacduro for treating hospital-acquired and ventilator-associated bacterial pneumonia caused by a cinetobacter baumannii-calcoaceticus complex; and Augtyro for the treatment of ROS proto-oncogene 1 and non-small cell lung cancer. The company has a strategic collaboration with Tesaro, Inc., NovoCure Ltd., Deciphera Pharmaceuticals, LLC, Paratek Bermuda Ltd., argent BV, Turning Point Therapeutics, Inc., Entasis Therapeutics Holdings Inc., Karuna Therapeutics, Inc., Pfizer Inc., Amgen Inc., and with Boehringer Ingelheim GmbH. The company was incorporated in 2013 and is based in Pudong, China.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the ZLAB discussion.
5 years, 4 months ago
Zai Lab Limited is currently in a long term uptrend where the price is trading 18.1% above its 200 day moving average.
From a valuation standpoint, the stock is 85.2% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 198.5.
Zai Lab Limited's total revenue rose by 540.3% to $30M since the same quarter in the previous year.
Its net income has increased by 99.7% to $-140K since the same quarter in the previous year.
Finally, its free cash flow fell by 48.9% to $-63M since the same quarter in the previous year.
Based on the above factors, Zai Lab Limited gets an overall score of 4/5.